Overview

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

One purpose of this study is to evaluate the effectiveness and safety in long term treatment for patients who completed preceding phase I/II study. The other purpose is to evaluate the effectiveness and safety of patients who are re-treated with this drug in recommended dose.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Bortezomib